KRAS and cancer: Known drivers of CRC have been identified through large-scale cancer genomesequencing efforts (Cancer Genome AtlasNetwork, 2012; Guinney et al.,2015) and include frequent oncogenic mutations in KRAS,BRAF and TP53, which are also common in othercancer types, such as melanoma (Krauthammer et al., 2012), and malignancies of the lung (Cancer Genome Atlas Research Network,2014) and pancreas (Bailey etal., 2016).